Blue Trust Inc. Grows Position in Owens & Minor, Inc. (NYSE:OMI)

Blue Trust Inc. lifted its position in Owens & Minor, Inc. (NYSE:OMI) by 176.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,787 shares of the company’s stock after buying an additional 1,780 shares during the quarter. Blue Trust Inc.’s holdings in Owens & Minor were worth $44,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Quarry LP grew its position in Owens & Minor by 290.1% during the second quarter. Quarry LP now owns 2,099 shares of the company’s stock valued at $28,000 after acquiring an additional 1,561 shares during the last quarter. Innealta Capital LLC bought a new position in shares of Owens & Minor in the second quarter worth approximately $43,000. DekaBank Deutsche Girozentrale grew its holdings in shares of Owens & Minor by 76.6% in the second quarter. DekaBank Deutsche Girozentrale now owns 3,126 shares of the company’s stock worth $43,000 after purchasing an additional 1,356 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Owens & Minor by 100.6% in the second quarter. Allspring Global Investments Holdings LLC now owns 6,071 shares of the company’s stock worth $82,000 after purchasing an additional 3,044 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in Owens & Minor in the second quarter valued at $82,000. 98.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on OMI shares. Citigroup upgraded shares of Owens & Minor from a “neutral” rating to a “buy” rating and dropped their target price for the company from $24.00 to $19.00 in a report on Friday, July 19th. StockNews.com cut shares of Owens & Minor from a “buy” rating to a “hold” rating in a report on Monday, August 26th. Barclays dropped their target price on shares of Owens & Minor from $23.00 to $18.00 and set an “equal weight” rating on the stock in a report on Monday, August 5th. Robert W. Baird dropped their price target on shares of Owens & Minor from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 16th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Owens & Minor from $22.00 to $18.00 and set an “underweight” rating on the stock in a research note on Wednesday, August 21st. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $20.00.

Owens & Minor Trading Up 5.1 %

Owens & Minor stock opened at $13.36 on Friday. The firm has a 50 day moving average of $14.62 and a 200 day moving average of $16.39. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -23.86, a P/E/G ratio of 0.42 and a beta of 0.39. Owens & Minor, Inc. has a 12-month low of $12.36 and a 12-month high of $28.35. The company has a current ratio of 1.09, a quick ratio of 0.51 and a debt-to-equity ratio of 2.17.

Owens & Minor (NYSE:OMI) last posted its earnings results on Friday, August 2nd. The company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.03. The firm had revenue of $2.67 billion during the quarter, compared to the consensus estimate of $2.65 billion. Owens & Minor had a positive return on equity of 14.66% and a negative net margin of 0.40%. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.18 EPS. As a group, research analysts predict that Owens & Minor, Inc. will post 1.57 earnings per share for the current year.

Owens & Minor Company Profile

Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers.